Glycosylated antibody

Abstract

The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

1 . A CHO cell line co-transfected with a first expression vector comprising a DNA sequence encoding the light chain of an antibody under the control of regulatory signals and a second expression vector comprising a DNA sequence encoding the heavy chain of the antibody under the control of regulatory signals, wherein each vector further comprises DNA encoding a selectable marker.  
     
     
         2 . A CHO cell line co-transfected with a first expression vector comprising cDNA encoding the light chain of a human or altered antibody under the control of regulatory signals and a second expression vector comprising cDNA encoding the heavy chain of the human or altered antibody under the control of regulatory signals.  
     
     
         3 . A CHO cell line as claimed in  claim 2 , wherein each vector further comprises an independently selectable marker.  
     
     
         4 . A CHO cell line as claimed in  claim 1 , wherein one of the markers is dominant.  
     
     
         5 . A CHO cell line as claimed in  claim 1 , wherein the markers are selected from adenosine deaminase, asparagine synthetase,  E. coli  trpBgene, Salmonella hisDgene, M2 mouse ribonucleotide reductase, human multidrug resistance gene, glutamine synthetase, xanthine guanine phosphoribosyl transferase, hygromycin B, neomycin gene and dihydrofolate reductase.  
     
     
         6 . A CHO cell line as claimed in  claim 1 , wherein one of the markers provides a basis for amplification.  
     
     
         7 . A CHO cell line as claimed in  claim 1 , wherein the cell line is dhfr− phenotype and the selectable marker encoded on one of said expression vectors is dhfr.  
     
     
         8 . A CHO cell line as claimed in  claim 7 , wherein the selectable marker encoded by the other expression vector is neomycin.  
     
     
         9 . A CHO cell line as claimed in  claim 1 , wherein the antibody is a chimeric or a CDR-grafted antibody.  
     
     
         10 . A CHO cell line as claimed in  claim 1 , wherein the antibody recognizes an antigen binding site on a T-cell marker.  
     
     
         11 . A CHO cell line as claimed in  claim 10 , wherein the antibody is raised against an antigen selected from CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD25, CD38, CDw52 and CD54.  
     
     
         12 . A CHO cell line as claimed in  claim 11 , which produces an anti-CDw52 antibody.  
     
     
         13 . A CHO cell line as claimed in  claim 1 , wherein the antibody recognizes an antigen binding site on a tumor cell marker.  
     
     
         14 . A human or altered antibody having CHO glycosylation.  
     
     
         15 . An antibody as claimed in  claim 14 , wherein the altered antibody is a chimeric or a CDR-grafted antibody.  
     
     
         16 . An antibody as claimed in  claim 15 , which is an anti-CDw52 antibody.  
     
     
         17 . A process for the preparation of an antibody as defined in  claim 14 , which comprises culturing a CHO cell engineered to express the antibody under antibody-producing conditions and recovering the antibody from the culture medium.  
     
     
         18 . A method for making a therapeutic medicament which comprises combining an antibody of  claim 14 , with a physiologically acceptable diluent or carrier.  
     
     
         19 . A method for treating severe vasculitis, systemic lupus, multiple sclerosis, graft vs. host disease, psoriasis, juvenile onset diabetes, thyroid disease, myasthenia gravis, transplant rejection or asthma which comprises administering a therapeutically effective amount of an antibody of  claim 14 .  
     
     
         20 . A method for treating cancer which comprises administering a cancer-treating effective amount of an antibody of  claim 14 .  
     
     
         21 . A method in accordance with  claim 20  wherein the cancer is non-Hodgkins lymphoma.  
     
     
         22 . A method for treating an infectious disease which comprises administering an effective amount of an antibody of  claim 14 .  
     
     
         23 . A method for treatment in accordance with  claim 19 , wherein the antibody is an anti-CDw52 antibody.  
     
     
         24 . A method for treating cancer in accordance with  claim 20 , wherein the antibody is an anti-CDw52 antibody.  
     
     
         25 . A method for treating an infectious disease in accordance with  claim 22 , wherein the antibody is an anti-CDw52 antibody.  
     
     
         26 . A formulation comprising a combination of a CHO-glycosylated antibody as defined in  claim 14 , and a physiologically acceptable diluent or carrier.